BioLeap, Inc.

NEW HOPE, PA · Founded 2009 · CIK 0001480519 · Biotech · Private

AI-powered mechanistic models for drug discovery that predict causal drug mechanisms and effects

bioleap.ai →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$5.0M
1 Form D · Jan 2010
201 months since last filing
Contracts
—
No federal contracts on record
Patents
9
6 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$5,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2341AION Healthspan, Inc.—$2.9M
2342Avm Biotechnology, LLC—$5.8M
2343INFIXION BIOSCIENCE, INC.——
2344BioLeap, Inc.—$5.0M
2345GENOPLAN INC.—$4.2M
2346LifeMine Therapeutics—$30M
2347MEDICON, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Ian CloudsdaleExecutive Officer
  • Stephen DavisExecutive Officer
  • Gerald EvansExecutive Officer
  • William FrezzaDirector
  • Brenda GavinDirector
  • John Kulp, Jr.Director · Executive Officer
  • David PomplianoDirector · Executive Officer

Patents

USPTO · 6 granted of 9

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.